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Abstract Malignant ureteral obstruction (MUO) caused by a primarily urological tumor or 
secondary to a late-stage malignancy can be difficult for the urologist to manage. Due to 
a lack of clinical data on the management of MUO, every case is particular and should 
be aborted individually.  
Lack of specific treatment, either palliative or definitive, can severely damage renal 
function and lifetime expectancy in patients, causing even more damage that could 
otherwise be avoided.  
Prompt management directed at the recovery of renal function is the main goal in 
such cases. Even after urinary flow is restored, life threatening post-obstructive diuresis 
needs to be managed.    
  
Keywords  malignant obstruction, bilateral obstruction, unilateral obstruction,  post obstructive diuresis, 
ureteral stent, percutaneous nephrostomy 
  
 
 
 
 
 
 
 
 
 
 
Highlights ✓ Malignant obstruction is a life-threatening pathology that requires prompt management for 
an optimal renal function. 
✓ Nephrostomy remains the only method that can reduce the external compressive 
obstruction with a rate of nearly 100%, but other methods should be considered.  
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Introduction 
Malignant ureteral obstruction (MUO) is a 
commonly encountered problem in late-stage 
gynecologic malignancies. However, numerous other 
malignant pathologies can also lead to ureteral 
obstruction either by nearby compression such as 
retroperitoneal tumors (1, 2), or by their direct invasion 
like that encountered in bladder tumors or malignant 
prostatic hyperplasia (3, 4). Often these patients develop 
urinary stasis and ureterohydronephrosis and they will 
evolve towards chronic kidney disease (5, 6). For 
patients with obstructive chronic kidney disease, urinary 
drainage may restore normal kidney function, but in 
some cases it may prove to be ineffective, these patients 
requiring hemodialysis (7, 8). Diabetes mellitus and 
other pathologies that associate immunodeficiency 
significantly increase the risk of urinary sepsis in 
patients with slowly progressing undiagnosed urinary 
retention (9, 10). These patients can present at the 
emergency department with a general altered state, 
complaining of pain, fever, chills, confusion, or 
obnubilation (encephalopathy secondary to the growth 
of nitrate retention products), with acute renal failure 
and ureterohydronephrosis (11). Other signs of septic 
shock usually found in such cases are: hypertension as 
well as hypotension (12, 13), tachyarrhytmias (as a 
result of the hydroelectrolytic imbalance) and heart 
failure (14, 15), disseminated intravascular coagulation, 
and venous thromboembolism (16). Therefore, special 
attention should be given to this type of patient. Prompt 
management is necessary for prevention or treatment of 
renal dysfunction and infection secondary to prolonged 
obstruction (17).  
Drainage with ureteral stents seems to be the first-
line therapy to relieve an obstruction caused by a 
malignant growing. The evolution of the design and 
materials of ureteral stents has dramatically changed 
throughout medical history, from the polyethylene tubes 
that were developed—thanks to the discovery of 
plastics—to bridge the gap in a cut ureteral using an 
animal model (18), to the modern double-J stent and the 
single-pigtail stent first introduced by Finney and 
colleagues (19). In a 10-year prospective study, ureteral 
stent caused varying degrees of discomfort to patients. 
However, none of the materials (4 types) used proved 
superior in terms of secondary manifestations for this 
foreign body in the urinary tract (20). 
Nephrostomy represents another alternative for 
palliative treatment of MUO.  Nephrostomy is a 
minimally invasive treatment for urinary obstruction 
with a marked hydronephrosis that creates an opening 
between the kidney and the skin, creating a diversion 
directly from the upper part of the urinary system (21). 
However, the median life expectancy in the patients 
with metastatic cancer that causes ureteral obstruction is 
generally under one year (22). 
Discussions 
This paper presents a brief review of the prevalence, 
etiology, pathophysiology, clinical presentation, 
diagnosis methods, and various treatments of MUO. 
Prevalence 
 A good marker suggestive of obstruction is 
represented by hydronephrosis. A total of 59,064 
autopsies with an age ranging from neonates to geriatric 
subjects reported an incidence in the general population 
to be 3.1% (23). The actual overall incidence of the 
ureteral obstruction due to malignancies is unknown, but 
clinically it is frequently encountered as a progressive 
pathology, leading to urinary blockage and presenting a 
risk of renal functional decline (24). 
Regarding etiology, only 21% of patients have 
MUO caused by a primary urological tumor (25). 
Generally, the ureteral obstruction can be the 
consequence of a direct tumor invasion, extrinsic 
ureteral compression, encasement by retroperitoneal 
lymph, or retroperitoneal fibrosis.  
Pathophysiology 
 The main variables that change in MUO are: 
glomerular filtration rate (GFR), renal blood flow 
(RBF), and ureteral pressure (UP). The pattern of 
changes among these variables is defined by the three 
phases, and is different for unilateral obstruction vs. 
bilateral obstruction (26). 
Unilateral obstruction. Animal experiments on 
unilateral obstruction have shown a triphasic pattern that 
differs from bilateral obstruction: 
• 1st phase (1-2h after obstruction): RBF- increases, 
high hydraulic pressure of fluid in the tubes, and high 
pressure in the collecting system (UP). 
• 2nd phase (3-4h after obstruction): RBF- decreases, 
UP- continues to increase. 
• 3rd phase (5h after obstruction): both RBF and UP 
decrease (27). 
GFR is maintained in 1st phase (the main reason 
being an increase in RBF), while in the second and third 
phase GFR decreases (28). 
Bilateral obstruction. Changes related to bilateral 
obstruction are different than unilateral obstruction (26). 
In the first 90 minutes after obstruction, the RBF 
increases, then slowly begins to decrease, UP increases 
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and remains elevated for a longer time than in unilateral 
obstruction (29). 
Post obstructive phase. Post obstructive phase is 
commonly encountered in bilateral obstruction; 
however, it is sometimes also seen in unilateral 
obstruction (30). MUO causes an immense retention of 
sodium, urea, water, and many other osmolar 
substances, able to lead to a profound diuresis 
afterwards (31). 
Clinical presentation 
Lower Urinary Tract Obstruction (LUTO) may be 
caused by benign processes such as benign prostatic 
hyperplasia (BPH), prostatic cystadenoma, or malignant 
tumors such as the bladder invasion distal to the trigone. 
LUTO can manifest as voiding dysfunction such as 
urgency, frequency, nocturia, incontinence, decreased 
stream, hesitancy, post void dribbling, and a sensation 
of inadequate emptying. Suprapubic pain or a palpable 
bladder indicates urinary retention. Infection may be 
present, and patients may experience dysuria (32-34). 
Acute Upper Urinary Tract Obstruction. Pelvic 
obstruction secondary to malignancies can be the 
consequence of stricture formation from recent surgery, 
or due to radiation induced strictures (35, 36). Acute 
upper urinary tract obstruction manifests differently, as 
dull, sharp, or colicky, intermittent or persistent pain, 
often radiating to iliac fossa. Nausea and vomiting are 
commonly associated with acute obstruction. Anuria 
suggests bilateral complete obstruction (37). 
Chronical Upper Urinary Tract Obstruction. Such 
obstructions are usually caused by an extrinsic tumor, or 
retroperitoneal fibrosis (38). Chronical upper urinary 
tract obstruction has a vague set of symptoms, usually 
flank discomfort, feelings of fullness, or nonspecific 
lethargy; sometimes this condition can be masked by 
urinary tract infections (24). 
Evaluation 
After performing anamnesis, physical examination, 
and obtaining basic serum analysis (e.g. electrolytes), 
imaging investigations are further considered for renal 
function assessment, as presented below. 
Ultrasonography. Renal ultrasonography can be 
considered as a first line intent in detecting the 
hydronephrosis. It is inexpensive, widely available, does 
not produce radiation, and can be used safely in pediatric 
patients and pregnant woman (39). Grey scale 
ultrasound has a reported sensitivity of 98% to 
determine the hydronephrosis (40). However, 
ultrasonography can only determine the anatomic 
dilatation of the urinary tract and not any functional 
obstruction (31). The Doppler mode can be used to 
identify the urine ejection at the bladder level (41). 
Nuclear medicine renography. Radioisotope 
renography is a form of imaging that uses radio labeling 
to determine renal functioning (42). The two most 
common radiolabeled pharmaceutical agents are 
Tc99m-MAG3 and Tc99m-DTPA (diethylene-triamine-
pentaacetate). Other radiolabeled pharmaceuticals are 
EC (Ethylenedicysteine) and 131-iodine labelled OIH 
(ortho-iodohippurate) (43). Tc99m-MAG3 and Tc99m-
DTPA are freely filtered and only eliminated by the 
proximal tubes. The halftime of these agents is used to 
evaluate the renal function: A halftime under 10 minutes 
is normal, while a halftime over 20 minutes is an 
indication of an obstruction (39).    
Computed Tomography and Magnetic Resonance 
Imaging. Computed tomography (CT) and magnetic 
resonance imaging (MRI) are increasingly valuable 
tools for assessing the urinary tract in adults and 
children. Modern CT scanners are fast and can scan the 
abdomen and pelvis typically in 5–7 seconds once the 
planning view (the ‘scout’ or ‘scanogram’) has been set 
up (44). Unenhanced helical CT diagnoses the ureteral 
stone disease with 95% sensitivity, 98% specificity, and 
97% accuracy (45). A CT urography scan can visualize 
the renal system in 3 phases: non-contrast, nephrogenic, 
and excretory (46). As a result, it can determinate stones 
and calcifications in non-contrast phase and determinate 
filling defect in excretory phase. It can also show 
extrinsic anatomic abnormalities (39). MRI provides 
similar anatomic information as a CT-scan. Because it 
does not produce ionizing radiation, it is safer in 
children and pregnant women. 
Urodynamics. Urodynamic investigation is a 
functional assessment of the lower urinary tract to 
provide objective pathophysiological explanation for 
symptoms and/or dysfunction of the lower and upper 
urinary tracts (47). 
Treatment 
Even after a complete resolution of pelvic 
malignancy, patients can still develop obstructive 
uropathy, not only from the disease, but from the 
treatment itself. Patients can develop many issues after 
surgical management, chemotherapy, and radiation 
treatment (35, 38, 48). The treatment of malignant 
uropathy varies for every particular case and depends 
substantially on the etiology of the uropathy. It may 
range from a definitive curative option to a palliative 
one. 
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Lower urinary tract obstruction. The main goal of 
lower urinary tract obstruction is bypassing the 
obstruction with a catheter. Initially, a Foley catheter 
can be used; if this is inefficient or the obstruction 
cannot be bypassed, a suprapubic tube should be 
considered. After the urinary flow is obtained through a 
bypass, the goal changes, being focused on recovering 
from the electrolyte abnormalities. At this point, the 
acute phase is resolved and definite management should 
be considered (31). 
Upper urinary tract obstruction implies ureteral 
stent or nephrostomy. Ureteral stents can be used as a 
long-term measure in patients with MUO (49), but the 
result depends on the etiology of the obstruction (50). In 
extrinsic etiologies, the stent tends to fail more 
frequently (51). The main goal of a stent is to create an 
optimal urinal flow, with minimal irritability (52). The 
latest metallic stents show promising results, insofar as 
overwhelming the extrinsic compressive forces. 
Another benefit of such stents is that it requires less 
frequent changing (49, 53). However, an ideal stent has 
not yet been invented, and current stents are not without 
morbidity. The most frequent side effects are: urinary 
frequency and urgency, dysuria, hematuria, and lumbar 
pain (20). Long term stenting seems to damage the 
ureterovesical junction; as a consequence, the junction 
will lose its tonicity and the ability for unidirectional 
flow of the urine, which can cause a recurrent reflux and 
pyelonephritis (54). 
Regarding nephrostomy, the research literature 
shows that the indication for nephrostomy is in 60% of 
cases due to malignant obstruction (55). It remains the 
only method that can reduce the external compressive 
obstruction, with a successful rate nearly of 100%, vs. 
50% for ureteral stents (56).  
Conclusions 
Malignant ureteral obstruction remains a major 
health problem that affects all categories of people 
around the world. Prompt diagnosis and treatment 
should be made to maintain optimal renal function. Even 
though there are numerous possibilities for the 
management of MUO (56), ureteral stenting and 
percutaneous nephrostomy are most widely used.  
Ureteral stenting appears to be the first line intent in 
most of cases (even though it presents a great chance of 
failing), especially in that the development of metal 
ureteral stents and other combinations shows promising 
results. The lack of randomized clinical data to compare 
the effectiveness and safety of the several procedures 
performed currently puts the physician in a decision-
making situation for every individual case, while the 
patient should be educated and integrally involved in the 
decision-making process.  
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